{"id":75216,"date":"2026-08-18T12:25:36","date_gmt":"2026-08-18T04:25:36","guid":{"rendered":"https:\/\/flcube.com\/?p=75216"},"modified":"2026-08-18T12:25:37","modified_gmt":"2026-08-18T04:25:37","slug":"european-commission-revokes-eu-marketing-authorisation-for-csl-and-vfmcrps-tavneos-avacopan-withdrawn-across-eu-and-eea-markets","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=75216","title":{"rendered":"European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP&#8217;s TAVNEOS \u2013 Avacopan Withdrawn Across EU and EEA Markets"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Vifor Fresenius Medical Care Renal Pharma (VFMCRP)<\/strong> and <strong>CSL<\/strong> announced that the <strong>European Commission (EC)<\/strong> has adopted a decision to <strong>revoke the marketing authorisation<\/strong> for <strong>TAVNEOS (avacopan)<\/strong> across <strong>European Union (EU)<\/strong> and <strong>European Economic Area (EEA)<\/strong> countries.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>European Commission (EC)<\/td><\/tr><tr><td><strong>Decision<\/strong><\/td><td>Revocation of marketing authorisation<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>TAVNEOS (avacopan)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Severe, active GPA or MPA in adult patients<\/td><\/tr><tr><td><strong>Affected Markets<\/strong><\/td><td>EU and EEA countries<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>18 Aug 2026<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>Not specified in the announcement<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Avacopan, an <strong>oral small\u2011molecule drug<\/strong>.<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Selective inhibitor of the <strong>complement C5a receptor C5aR1<\/strong>.<\/li>\n\n\n\n<li><strong>Regimen:<\/strong> Used <strong>in combination with rituximab or cyclophosphamide<\/strong>.<\/li>\n\n\n\n<li><strong>Indication:<\/strong> Treatment of adult patients with severe, active <strong>granulomatosis with polyangiitis (GPA)<\/strong> or <strong>microscopic polyangiitis (MPA)<\/strong>.<\/li>\n\n\n\n<li><strong>Origin:<\/strong> Originally developed by <strong>ChemoCentryx<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-commercial-amp-licensing-background\" class=\"wp-block-heading\">Commercial &amp; Licensing Background<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Commercialisation Structure:<\/strong> Avacopan is commercialised <strong>outside the United States and in select countries<\/strong> by <strong>CSL<\/strong>, its affiliates and partners.<\/li>\n\n\n\n<li><strong>Agreement Basis:<\/strong> Commercialisation proceeds under a <strong>collaboration and licensing agreement<\/strong> between <strong>VFMCRP<\/strong> and <strong>ChemoCentryx<\/strong>.<\/li>\n\n\n\n<li><strong>U.S. Market:<\/strong> The revocation decision applies to EU and EEA markets; the announcement does not address the drug&#8217;s status in the United States.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Access Implications:<\/strong> The EC decision removes TAVNEOS from the treatment landscape for GPA and MPA patients across the EU and EEA, narrowing options for a rare, serious autoimmune condition.<\/li>\n\n\n\n<li><strong>Portfolio Effect:<\/strong> For <strong>CSL<\/strong> and <strong>VFMCRP<\/strong>, the revocation eliminates a commercial asset in European nephrology and vasculitis markets, with implications for regional revenue and pipeline strategy.<\/li>\n\n\n\n<li><strong>Regulatory Divergence:<\/strong> With the product&#8217;s fate now split across jurisdictions, attention turns to how the decision interacts with approvals and commercialisation in the United States and other select markets.<\/li>\n\n\n\n<li><strong>Strategic Positioning:<\/strong> The outcome underscores the regulatory risk attached to orphan and specialist therapies, where post\u2011authorisation obligations can determine a product&#8217;s long\u2011term commercial viability.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the implementation and consequences of the EC decision on TAVNEOS. Actual results may differ due to risks including regulatory implementation, market dynamics and competitive developments.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL announced that the European Commission (EC)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":75218,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[],"class_list":["post-75216","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP&#039;s TAVNEOS \u2013 Avacopan Withdrawn Across EU and EEA Markets - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL announced that the European Commission (EC) has adopted a decision to revoke the marketing authorisation for TAVNEOS (avacopan) across European Union (EU) and European Economic Area (EEA) countries.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=75216\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP&#039;s TAVNEOS \u2013 Avacopan Withdrawn Across EU and EEA Markets\" \/>\n<meta property=\"og:description\" content=\"Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL announced that the European Commission (EC) has adopted a decision to revoke the marketing authorisation for TAVNEOS (avacopan) across European Union (EU) and European Economic Area (EEA) countries.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=75216\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-18T04:25:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-18T04:25:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1803.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75216#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75216\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP&#8217;s TAVNEOS \u2013 Avacopan Withdrawn Across EU and EEA Markets\",\"datePublished\":\"2026-08-18T04:25:36+00:00\",\"dateModified\":\"2026-08-18T04:25:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75216\"},\"wordCount\":367,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75216#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/1803.webp\",\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=75216#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75216\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=75216\",\"name\":\"European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP's TAVNEOS \u2013 Avacopan Withdrawn Across EU and EEA Markets - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75216#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75216#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/1803.webp\",\"datePublished\":\"2026-08-18T04:25:36+00:00\",\"dateModified\":\"2026-08-18T04:25:37+00:00\",\"description\":\"Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL announced that the European Commission (EC) has adopted a decision to revoke the marketing authorisation for TAVNEOS (avacopan) across European Union (EU) and European Economic Area (EEA) countries.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75216#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=75216\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75216#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/1803.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/1803.webp\",\"width\":1080,\"height\":608,\"caption\":\"European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP's TAVNEOS \u2013 Avacopan Withdrawn Across EU and EEA Markets\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75216#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP&#8217;s TAVNEOS \u2013 Avacopan Withdrawn Across EU and EEA Markets\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP's TAVNEOS \u2013 Avacopan Withdrawn Across EU and EEA Markets - Insight, China&#039;s Pharmaceutical Industry","description":"Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL announced that the European Commission (EC) has adopted a decision to revoke the marketing authorisation for TAVNEOS (avacopan) across European Union (EU) and European Economic Area (EEA) countries.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=75216","og_locale":"en_US","og_type":"article","og_title":"European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP's TAVNEOS \u2013 Avacopan Withdrawn Across EU and EEA Markets","og_description":"Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL announced that the European Commission (EC) has adopted a decision to revoke the marketing authorisation for TAVNEOS (avacopan) across European Union (EU) and European Economic Area (EEA) countries.","og_url":"https:\/\/flcube.com\/?p=75216","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-18T04:25:36+00:00","article_modified_time":"2026-08-18T04:25:37+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1803.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=75216#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=75216"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP&#8217;s TAVNEOS \u2013 Avacopan Withdrawn Across EU and EEA Markets","datePublished":"2026-08-18T04:25:36+00:00","dateModified":"2026-08-18T04:25:37+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=75216"},"wordCount":367,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=75216#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1803.webp","articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=75216#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=75216","url":"https:\/\/flcube.com\/?p=75216","name":"European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP's TAVNEOS \u2013 Avacopan Withdrawn Across EU and EEA Markets - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=75216#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=75216#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1803.webp","datePublished":"2026-08-18T04:25:36+00:00","dateModified":"2026-08-18T04:25:37+00:00","description":"Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL announced that the European Commission (EC) has adopted a decision to revoke the marketing authorisation for TAVNEOS (avacopan) across European Union (EU) and European Economic Area (EEA) countries.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=75216#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=75216"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=75216#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1803.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1803.webp","width":1080,"height":608,"caption":"European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP's TAVNEOS \u2013 Avacopan Withdrawn Across EU and EEA Markets"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=75216#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP&#8217;s TAVNEOS \u2013 Avacopan Withdrawn Across EU and EEA Markets"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1803.webp","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75216","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=75216"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75216\/revisions"}],"predecessor-version":[{"id":75219,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75216\/revisions\/75219"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/75218"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=75216"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=75216"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=75216"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}